J3 Bioscience, Inc. Appoints John Fair as New President & CEO
Salt Lake City, UT – March 24, 2025 – J3 Bioscience, Inc., a commercialization stage startup medical device company focused on women’s health, today announced the appointment of John Fair as its new President and Chief Executive Officer, effective immediately. Founder and current CEO Tyler McCabe will transition to the role of Chief Operating Officer.
Mr. Fair, who has served on J3’s board of directors for the past year, brings deep experience and a strong track record in women’s health, including leadership in strategic planning and commercialization across the pharmaceutical, biotech, and medical device sectors. His background includes:
- More than 20 years of senior leadership in biopharma and medical devices
- Expertise in corporate and business development, brand strategy, and both provider- and consumer-facing commercialization
- A history of securing major partnerships in the women’s health space, including one of the largest deals in the reproductive health category with Bayer Healthcare
- Proven success in capital formation, with over $80M in institutional funding raised
- Extensive experience with innovative consumer brands
Most recently, Mr. Fair served as Chief Business Officer at a life sciences company developing next-generation pharmaceutical therapies and diagnostic solutions for serious women’s health conditions. Prior to that, he was Chief Business Development & Chief Commercial Officer at Daré Bioscience, where he led commercialization efforts across a portfolio of women’s health therapeutics and devices.
"John brings a powerful blend of strategic vision and industry expertise, making him the perfect leader to drive our goals and objectives during this next phase," stated Dr. McCabe. "His proficiency in leveraging consumer insights, building strong brands, fostering growth, and securing critical strategic partnerships with category leaders aligns seamlessly with J3's ambitions. I've personally known John and believe his talents are exactly what we need to add significant value to the company. I look forward to supporting him as we continue advancing our mission of successfully commercializing LivRing and expanding J3’s corporate outreach."
"I'm excited to lead J3 Bioscience as we push the boundaries of what’s possible in women’s health," said John Fair, President and CEO. "The company's commitment to science-driven innovation aligns with my passion for advancing accessible, impactful healthcare. I look forward to partnering with this exceptional team to drive meaningful growth and bring forward new solutions that transform the lives of women."
The board of directors unanimously approved Mr. Fair’s appointment, citing his leadership, strategic expertise, and track record in commercializing women’s health products as key factors in their decision.
About J3 Bioscience, Inc.
J3 Bioscience, Inc. is a women’s health medical device startup headquartered in Salt Lake City, Utah.
Media Contact:
R. Tyler McCabe, Chief Operating Officer, [email protected]
J3 Bioscience, Inc. Announces Commercial Launch of Groundbreaking LivRing®
Salt Lake City, UT – September 18, 2024.
J3 Bioscience, Inc., a startup women’s health medical device company, today announced the commercial launch of a first-of-its-kind medical device, LivRing®. This innovative device has the potential to conveniently ease painful sex due to vaginal dryness and improve the lives of countless women in the United States. LivRing® is available online only through liv-ring.com.
LivRing® is the culmination of years of research and development, combining cutting-edge technology with a deep understanding of patient needs. The device is a patented lubricating intravaginal ring. It is designed to moisturize and lubricate the vagina, enhance the ease and comfort of intimate sexual activity, and supplement the body’s natural lubrication. It contains no hormones/drugs, is long-lasting (7 days each), and self-inserted weekly. It is the only over-the counter consumer product that provides long lasting controlled-release of a moisturizing lubricant. Fifty percent of all post-menopausal women experience the pain and discomfort of chronic vaginal dryness. Twenty percent of pre-menopausal women also experience dryness.
“This is an exciting day for the state of women’s health in the U.S.,” said Tyler McCabe, PhD, CEO of J3 Bioscience, Inc. “LivRing® is a game changer for the vaginal lubrication market. We also are committed to development of additional follow-on products to further improve women’s health.”
LivRing® has received regulatory clearance and is now available for use throughout the United States. Visit the online store at liv-ring.com.
About J3 Bioscience
J3 Bioscience, Inc. is a startup women’s health medical device company headquartered in Salt Lake City, Utah.
CONTACT:
R. Tyler McCabe, PhD
Chief Executive Officer, J3 Bioscience, Inc.
[email protected]
J3 Bioscience, Inc. Announces Appointment of Three New Directors to Board; Retirement of One
Salt Lake City, UT – May 23, 2024.
J3 Bioscience, Inc., a commercialization stage women’s health medical device company, today announced the appointment of three new members to its Board of Directors: John Fair, Dr. Keith Marmer, and Dr. Stephanie Singer.
John brings 20 years of experience in women’s health commercial strategy, fundraising and business development and currently serves as Global Head of Partnering & Corporate Development at Heranova Lifesciences. His insights and leadership will be invaluable as J3 Bioscience continues to commercialize its lead product, LivRing®.
Keith has 33 years’ experience in company formation, corporate strategy, leadership, business development, licensing, investment, technology development, patent strategy and clinical practice as an entrepreneur, executive and practitioner. He currently serves as Managing Partner of UVB Capital, a venture fund focused on partnering with early-stage life science companies. Prior to co-founding UVB Capital, Keith was Chief Innovation & Economic Engagement Officer at the University of Utah. His experience will be instrumental in guiding J3 Bioscience's strategic direction and growth.
Stephanie is a Board-certified OB/GYN since 1999, specializing since 2019 solely in gynecology, minimally invasive gynecologic surgery and women’s health, with great emphasis on hormone balance, sexual health and healthy aging. Her expertise will be essential as J3 Bioscience commercializes its lead product and develops its follow-on products with its patented ring platform.
Dr. Jayne Carney has advised the Company that she will retire from the Board later this month concurrent with her 80th birthday. The Company extends its deepest gratitude to Jayne for her eight years of service on the Company’s Board of Directors.
"We are very excited to enhance our Board with these high caliber professionals at this pivotal time for the Company," said R. Tyler McCabe, President and CEO of the Company. "Their contributions will help the Company achieve its strategic goals in many important ways."
With the addition of these three new directors and the retirement of Dr. Carney, J3 Bioscience's Board now consists of nine members with diverse backgrounds and expertise, further strengthening the company's governance and strategic oversight.
About J3 Bioscience
J3 Bio is a commercialization stage women’s health medical device company. The Company’s lead product, known as the LivRing® (formerly termed VR101), is an FDA cleared (K203377), patented and unique lubricating intravaginal ring (IVR). It is designed to moisturize and lubricate the vagina, enhance the ease and comfort of intimate sexual activity, and supplement the body's natural lubrication. It contains no hormones/drugs, is long-lasting (7 days each), and self-inserted weekly. It is the only IVR that provides long-lasting controlled-release of a moisturizing lubricant.
CONTACT:
R. Tyler McCabe, PhD
Chief Executive Officer, J3 Bioscience, Inc.
[email protected]
J3 Bioscience Receives FDA Clearance on Lead Product for Unmet Women’s Vaginal Health and Wellness Needs
PRESS RELEASE - October 27, 2021 – Salt Lake City, UT.
Patented LivRing® is an intravaginal ring that provides long-lasting, controlled release of moisture to supplement the body’s natural lubrication and enhance the ease and comfort of sexual activity.
J3 Bioscience, Inc. today announced that its first vaginal health product, known as the “LivRing®” (aka VR101 Lubricating Intravaginal Ring), recently received 510(k) Premarket Notification clearance from the U.S. Food and Drug Administration (FDA). The LivRing is a patented, intravaginal ring (IVR) that functions as a long-term (up to 7 days) lubricating vaginal moisturizer to supplement the body’s natural lubrication and enhance the ease and comfort of intimate sexual activity. The LivRing is the longest-lasting vaginal lubricating product that will be available over-the-counter (OTC).
The LivRing®
“LivRing will solve the substantial unmet vaginal discomfort need,” said R. Tyler McCabe, PhD, President/CEO of J3 Bioscience. “The Company is thrilled to receive FDA clearance on its first and lead product as this definitely will provide a benefit to certain women and women’s health.” In addition, Dr. McCabe noted, “The LivRing is an innovative product. It contains no drugs or hormones and releases a lubricating moisturizer. Each ring is long-lasting and effective for up to 7 days. In addition, it is safe, simple, and easy to self-insert. LivRing does not interrupt intimacy or spontaneity, and is intended for continuous, repeat use when each ring is replaced weekly. Clinical study participants reported very high satisfaction and confidence levels.”
While ideal for post-menopausal women, the LivRing was clinically tested in women 21 years and older who qualified for the study. Women who will benefit include those experiencing discomfort from vaginal dryness, including potential dryness from medications and certain medical conditions. The LivRing is the only OTC product that is intended to provide long-lasting (seven days each ring) controlled-release of a natural lubricating moisturizer. The Indications for Use are: LivRing (VR101 Lubricating Intravaginal Ring) is a personal lubricant for vaginal application, intended to moisturize and lubricate, to enhance the ease and comfort of intimate sexual activity, and supplement the body’s natural lubrication. This product is compatible with natural rubber latex and synthetic (polyurethane and polyisoprene) male condoms and FC2 female condoms.
The LivRing is expected to be commercially available in the U.S. in the first half of 2022. Commercialization in Europe is expected later in 2022 after the product receives its CE mark.
About J3 Bioscience
J3 Bioscience, Inc., based in Salt Lake City, UT, is a commercialization-stage women’s health company focused on using its patented, proprietary technologies to create unique products addressing unmet needs for women’s vaginal health and wellness. The Company’s lead product, known as the LivRing, is a unique, clinically proven, and FDA-cleared intravaginal ring (IVR) that provides natural lubrication and moisture to women experiencing vaginal dryness. Using the same patent protected intellectual property platform, J3 Bioscience has programs in various stages of development for additional IVR products, including “light” LivRing, a pH balancing ring, and a probiotic ring.
CONTACT:
R. Tyler McCabe, PhD
Chief Executive Officer, J3 Bioscience, Inc.
[email protected]